Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Claire Wallace
Advertisement
President, microbiology, specialty diagnostics, Thermo Fisher Scientific
Articles by Claire Wallace
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
